Relation between impaired antiplatelet response to clopidogrel and possible pleiotropic effects

Journal of Thrombosis and Thrombolysis

Volumn 24, Issue 3, 2007, Pages 301-305

  Malek, Lukasz A ^a   Grabowski, Marcin ^a   Spiewak, Mateusz ^a   Filipiak, Krzysztof J ^a   Szpotanska, Monika ^a   Imiela, Tomasz ^a   Huczek, Zenon ^a   Bobilewicz, Dagna ^a   Opolski, Grzegorz ^a  

^a MEDICAL UNIVERSITY OF WARSAW   (Poland)

Author keywords

Clopidogrel; Drugr esponse; Platelets; Pleiotropic effects

Indexed keywords

ACETYLSALICYLIC ACID; ADENOSINE DIPHOSPHATE; ADRENALIN; ATORVASTATIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; C REACTIVE PROTEIN; CLOPIDOGREL; COLLAGEN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HEPARIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW MOLECULAR WEIGHT HEPARIN; SIMVASTATIN;

ADULT; AGED; ANTIINFLAMMATORY ACTIVITY; ARTICLE; BLOOD CLOTTING PARAMETERS; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG ELUTING STENT; DRUG RESPONSE; DRUG SENSITIVITY; FEMALE; HEART INFARCTION; HUMAN; LOADING DRUG DOSE; MALE; PERCUTANEOUS CORONARY INTERVENTION; PLEIOTROPY; PRIORITY JOURNAL; REFERENCE VALUE; ST SEGMENT ELEVATION; TREATMENT DURATION;

AGED; ASPIRIN; BLOOD PLATELETS; C-REACTIVE PROTEIN; DRUG RESISTANCE; FEMALE; HUMANS; INFLAMMATION; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PLATELET AGGREGATION INHIBITORS; PLATELET FUNCTION TESTS; STENTS; TICLOPIDINE;

EID: 35448934814     PISSN: 09295305     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11239-007-0026-8     Document Type: Article

References (16)

1. Task Force for Percutaneous Coronary Interventions of the European Society of Cardiology. Task Force for Percutaneous Coronary Interventions of the European Society of Cardiology (2005) Guidelines for percutaneous coronary interventions: The task force for percutaneous coronary interventions of the European society of cardiology. Eur Heart J 26:804-847
2. Cattaneo M (2004) Aspirin and clopidogrel. Efficacy, safety, and the issue of drug resistance. Arterioscler Thromb Vasc Biol 24:1980-1987
3. Wang TH, Bhatt DL, Topol EJ (2006) Aspirin and clopidogrel resistance: an emerging clinical entity. Eur Heart J 27:647-654
4. Nguyen TA, Diodati JG, Pharand C (2005) Resistance to clopidogrel: A review of the evidence. J Am Coll Cardiol 45:1157-1164
5. Szczeklik A, Musial J, Undas A, Sanak M (2005) Aspirin resistance. J Thromb Haemost 9:2015-2021
6. Serebruany VL, Steinhubl SR, Berger PB, Malinin AI, Bhatt DL, Topol EJ (2005) Variability in platelet responsiveness to clopidogrel among 544 individuals. J Am Coll Cardiol 45:246-251
7. Chew DP, Bhatt DL, Robbins MA (2001) Effects of clopidogrel added to aspirin before percutaneous coronary intervention on the risk associated with C-reactive protein. Am J Cardiol 88:672-674
8. Yusuf S, Zhao F, Mehta SR, Chrolavicius S, Tognoni G, Fox KK (2001) Clopidogrel in Ustable Angina to Prevent Recurrent Events Trial Investigators. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST segment elevation [published corrections appear in N Engl J Med. 2001;345:1506 and 1716]. N Engl J Med 345:494-502
9. Angiolillo DJ, Fernandez-Ortiz A, Bernardo E et al (2006) Clopidogrel withdrawal is associated with proinflammatory and prothrombotic effects in patients with diabetes and coronary artery disease. Diabetes 55:780-784
10. Ferreiros ER, Boissonnet CP, Pizarro R et al (1999) Independent prognostic value of elevated C-reactive protein in unstable angina. Circulation 100:1958-1963
11. Toss H, Lindahl B, Siegbahn A, Wallentin L (1997) Prognostic influence of increased fibrinogen and C-reactive protein levels in unstable coronary artery disease Circulation 96:4204-4210
12. Heeschen C, Dimmeler S, Hamm CW et al (2003) CAPTURE Study Investigators. Soluble CD40 ligand in acute coronary syndromes N Engl J Med 348:1104-1111
13. Cermak J, Key NS, Bach RR, Balla J, Jacob HS, Vercellotti GM (1993) C-reactive protein induces human peripheral blood monocytes to synthesize tissue factor. Blood 82:513-520
14. Dibra A, Mehilli J, Braun S et al (2005) Inflammatory response after intervention assessed by serial C-reactive protein measurements correlates with restenosis in patients treated with coronary stenting. Am Heart J 150:344-350
15. Hayward CP, Harrison P, Cattaneo M, Ortel TL, Rao AK (2006) The platelet physiology subcommittee of the scientific and standardization committee of the international society on thrombosis and haemostasis. Platelet function analyzer (PFA)-100 ® closure time in the evaluation of platelet disorders and platelet function. J Thromb Haemost 4:312-319
16. Azar RR, Kassab R, Zoghbi A et al (2006) Effects of clopidogrel on soluble CD40 ligand and on high-sensitivity C-reactive protein in patients with stable coronary artery disease. Am Heart J 151:521.e1-521.e4